Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 5.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 98,025 shares of the company’s stock after purchasing an additional 4,871 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Phathom Pharmaceuticals worth $1,772,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Huntington National Bank lifted its position in Phathom Pharmaceuticals by 62.2% in the third quarter. Huntington National Bank now owns 1,471 shares of the company’s stock valued at $27,000 after acquiring an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Phathom Pharmaceuticals by 28.6% in the 3rd quarter. US Bancorp DE now owns 5,248 shares of the company’s stock valued at $95,000 after purchasing an additional 1,166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Phathom Pharmaceuticals by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after purchasing an additional 2,987 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Phathom Pharmaceuticals by 10.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares during the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

Insider Activity at Phathom Pharmaceuticals

In other news, Director Frank Karbe acquired 12,500 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average price of $7.93 per share, for a total transaction of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares in the company, valued at approximately $452,010. This trade represents a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 24.10% of the stock is currently owned by insiders.

Phathom Pharmaceuticals Trading Up 3.2 %

Shares of PHAT stock opened at $8.14 on Tuesday. The company has a market capitalization of $556.61 million, a P/E ratio of -1.43 and a beta of 0.56. The business’s 50 day moving average is $12.74 and its two-hundred day moving average is $13.17. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.